Transcode Therapeutics, Inc. (RNAZ) stock
RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.32−0.07 (-5.06%)
Close on Nov 13, 2026Market cap $1.34MP/E –Yield –
Transcode Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Transcode Therapeutics's ebitda for the twelve months ending Jun 30, 2026 was -$45.10M. For fiscal 2025 it was -$27.97M. The highest annual figure on record is -$726.60K in fiscal 2020.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$27.97M | – |
| FY2024 | Dec 31, 2024 | -$15.57M | – |
| FY2023 | Dec 31, 2023 | -$19.30M | – |
| FY2022 | Dec 31, 2022 | -$18.54M | – |
| FY2021 | Dec 31, 2021 | -$6.11M | – |
| FY2020 | Dec 31, 2020 | -$726.60K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$6.77M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.73M | – |
| Q4 FY2025 | Dec 31, 2025 | -$16.04M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.56M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$3.16M | – |
| Q4 FY2024 | Dec 31, 2024 | -$5.08M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.15M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.08M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.26M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.07M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.28M | – |
| Q2 FY2023 | Jun 30, 2023 | -$5.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$4.86M | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.47M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$4.68M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.96M | – |
| Q1 FY2021 | Mar 31, 2021 | -$448.21K | – |
See a number that looks wrong?